Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 3.78IPCO.TO 0.08DC.A.TO 0.1NESN-SIX 0MCK 9.94GOOG -1.89XLV -0.22TEVA 0.83
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.95
-0.02 (0.07%)
as of Aug 25, 2026, 1:34:22 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 24, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as its revenue streams have been impacted by the end of the COVID vaccine boom and a looming patent cliff. Many experts express concerns over the company's limited pipeline for new blockbuster drugs, especially as previous successful drugs have come off patent. Despite these challenges, Pfizer offers an attractive dividend yield which has been highlighted across many reviews, providing a tempting incentive for investors. Some experts suggest it might be a good long-term hold due to potential growth in areas like oncology and obesity, although the company's future growth prospects remain uncertain. The general sentiment suggests that while some see PFE as a value play, caution is advised given the current dynamics of its business model.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
DON'T BUY

Pfizer Inc(PFE)

Apr 10, 2002
Has a good pipeline. Should improve towards the end of the year.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$39.34

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 02, 2002
Great pipeline of products, but has trouble breaking through the $44 level.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$39.91

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 28, 2002
Very expensive now. 8/10 X Book. Has some potential, but caution.
Photo of Ross HealyRoss HealyUnlock Rating
$39.74

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 15, 2002
Trading at high multiples.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. ScUnlock Rating
$41.37

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 12, 2002
A great long term hold for growth. Strong pipeline.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$39.85

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 08, 2002
Prefers Glaxco Smith Klein.
Photo of David DriscollDavid DriscollUnlock Rating
$40.01

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 22, 2002
Prefers this and J&J over Merk. Will eventually give a 15/20% return.
Photo of Brad WillockBrad WillockUnlock Rating
$40.65

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 17, 2002
At a good price. Have a good drug pipeline. A premium company. Earnings growth should be 20% plus.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$40.13

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 11, 2002
(Was a top pick on June 14 down 5%) Has the best patent protection folio. Should grow 25% in 2002 and 15% for the next two years.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$40.60

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 11, 2002
They have a good product line plus good new product development is excellent. Very cheap now.
Photo of Steven WipperstegSteven WipperstegUnlock Rating
$40.60

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 08, 2002
Good pipeline. Likes the price.
Photo of Jeff MorrisonJeff MorrisonUnlock Rating
$39.59

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 07, 2002
Likes the pharmaceutical sector. Has a good pipeline for its drugs.
Photo of Neil MurdockNeil MurdockUnlock Rating
$39.70

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 04, 2002
Likes the sector. Well positioned. Prefers over Merc.
Photo of John ZechnerJohn ZechnerUnlock Rating
$39.40

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 03, 2002
(Was a top pick on Sept 26 up 3.5%) Will have to buy some biotechs to keep their pipelines growing.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$39.70

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 02, 2002
(Was a top pick on Sept 10 up 4.4%) Not the best time to buy pharmaceuticals. Buy under $40.
Photo of Brad WillockBrad WillockUnlock Rating
$39.90

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 826 to 840 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -2.98$99.89
TFPM 0$
OGC.TO -0.83$42.39
SLB 0.045$54.045
ARG.TO 0.33$8.55

Today's Top Picks

SII.TO 3.78$190.97
IPCO.TO 0.08$35.3
DC.A.TO 0.1$5.25
NESN-SIX 0$
MCK 9.94$883.73

Popular Articles

Latest Sell Signals

RKLB -1.05$67.23
INTC 1.21$88.47
MSFT 1.63$488.94
WSP.TO -0.96$191.32
CLS.TO 10.72$418.08

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like